Literature DB >> 24791860

Unnatural killer cells to prevent bloodborne metastasis: inspiration from biology and engineering.

Michael J Mitchell1, Michael R King.   

Abstract

Metastasis contributes to over 90% of cancer-related deaths. Many types of cancer metastasize via the bloodstream, where circulating tumor cells (CTCs) originating from the primary tumor can undergo selectin-mediated adhesion with the blood vessel wall and subsequently transmigrate to anatomically distant organs. In an effort to neutralize CTCs with the potential to form metastases, a new therapeutic approach has been developed in which circulating leukocytes are functionalized to target and kill cancer cells in the bloodstream. This approach mimics the cytotoxic activity of natural killer cells and the chemical engineering concept of a fluidized bed reactor, which increases the surface area for surface-catalyzed reactions. The resulting 'unnatural killer cells', proven effective in vitro with human blood and also in the living mouse, holds promise in neutralizing CTCs to interrupt the metastasis process.

Entities:  

Keywords:  E-selectin; TRAIL; circulating tumor cells; leukocyte

Mesh:

Substances:

Year:  2014        PMID: 24791860      PMCID: PMC5629038          DOI: 10.1586/14737140.2014.916619

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  19 in total

1.  Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.

Authors:  Roy S Herbst; S Gail Eckhardt; Razelle Kurzrock; Scot Ebbinghaus; Peter J O'Dwyer; Michael S Gordon; William Novotny; Meredith A Goldwasser; Tanyifor M Tohnya; Bert L Lum; Avi Ashkenazi; Adrian M Jubb; David S Mendelson
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types.

Authors:  X D Zhang; T Nguyen; W D Thomas; J E Sanders; P Hersey
Journal:  FEBS Lett       Date:  2000-10-06       Impact factor: 4.124

3.  MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1.

Authors:  Jennifer J Rahn; Jeffrey W Chow; Garnet J Horne; Brian K Mah; Joanne T Emerman; Pat Hoffman; Judith C Hugh
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

4.  E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells.

Authors:  Michael J Mitchell; Christina S Chen; Varun Ponmudi; Andrew D Hughes; Michael R King
Journal:  J Control Release       Date:  2012-03-01       Impact factor: 9.776

5.  TRAIL-coated leukocytes that kill cancer cells in the circulation.

Authors:  Michael J Mitchell; Elizabeth Wayne; Kuldeepsinh Rana; Chris B Schaffer; Michael R King
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-06       Impact factor: 11.205

6.  Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation.

Authors:  Dorrah Deeb; Hao Jiang; Xiaohua Gao; Mikehl S Hafner; Henry Wong; George Divine; Robert A Chapman; Scott A Dulchavsky; Subhash C Gautam
Journal:  Mol Cancer Ther       Date:  2004-07       Impact factor: 6.261

7.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.

Authors:  Isaiah J Fidler
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

8.  Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms.

Authors:  Braedon McDonald; Jonathan Spicer; Betty Giannais; Lucia Fallavollita; Pnina Brodt; Lorenzo E Ferri
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

9.  Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectin.

Authors:  Kuldeepsinh Rana; Cynthia A Reinhart-King; Michael R King
Journal:  Mol Pharm       Date:  2012-07-02       Impact factor: 4.939

10.  Computational and experimental models of cancer cell response to fluid shear stress.

Authors:  Michael J Mitchell; Michael R King
Journal:  Front Oncol       Date:  2013-03-05       Impact factor: 6.244

View more
  6 in total

1.  Surfactant functionalization induces robust, differential adhesion of tumor cells and blood cells to charged nanotube-coated biomaterials under flow.

Authors:  Michael J Mitchell; Carlos A Castellanos; Michael R King
Journal:  Biomaterials       Date:  2015-04-17       Impact factor: 12.479

Review 2.  Leukocytes as carriers for targeted cancer drug delivery.

Authors:  Michael J Mitchell; Michael R King
Journal:  Expert Opin Drug Deliv       Date:  2014-10-01       Impact factor: 6.648

3.  Immobilized surfactant-nanotube complexes support selectin-mediated capture of viable circulating tumor cells in the absence of capture antibodies.

Authors:  Michael J Mitchell; Carlos A Castellanos; Michael R King
Journal:  J Biomed Mater Res A       Date:  2015-03-30       Impact factor: 4.396

Review 4.  Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy.

Authors:  Pedro P G Guimarães; Stephanie Gaglione; Tomasz Sewastianik; Ruben D Carrasco; Robert Langer; Michael J Mitchell
Journal:  ACS Nano       Date:  2018-02-06       Impact factor: 15.881

5.  High Shear Stresses under Exercise Condition Destroy Circulating Tumor Cells in a Microfluidic System.

Authors:  Sagar Regmi; Afu Fu; Kathy Qian Luo
Journal:  Sci Rep       Date:  2017-01-05       Impact factor: 4.379

6.  Mass Action Kinetic Model of Apoptosis by TRAIL-Functionalized Leukocytes.

Authors:  Emily E Lederman; Jacob M Hope; Michael R King
Journal:  Front Oncol       Date:  2018-10-29       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.